The effects of bioactive compounds on Alzheimer’s disease and Mild cognitive impairment

Abstract

As the prevalence and rate of Alzheimer’s disease are increasing around world, identifying effective treatments to manage cognitive impairment and neurodegeneration has become a global health priority. Decades of scientific research have led to a more comprehensive understanding of Alzheimer’s Disease and Mild Cognitive Impairment (MCI), a transitional stage of accelerated cognitive decline. This understanding has enabled researchers to envision and develop novel Alzheimer’s Disease therapies, including the use of bioactive compounds found in plants and animals. Within the past 15 years, a significant amount of clinical research has been published documenting the effects specific bioactive compounds have on patients with Alzheimer’s Disease and MCI. This article reviews the results of this research, along with relevant epidemiological studies, measures of cognition, and disease pathologies to discuss whether sufficient evidence exists to support the use of specific bioactive compounds by individuals diagnosed with Alzheimer’s Disease and MCI. The results of clinical trials within the last 15 years do not conclusively prove that the studied quantities of vitamin B, Omega-3 fatty acids, or bioactive compounds within Fortasyn Connect are beneficial for use in the management of Alzheimer’s Disease or MCI. Additionally, the documented effects of these bioactive compounds do not warrant development of a functional food product to help manage AD or MCI.